Keytruda

Ten ways multiple myeloma treatment is changingAs multiple myeloma treatment improvements continue, it’s important for managed care executives to get out in front of these 10 changes on the horizon.
FDA warns about deaths in cancer drug trials
FDA warns about deaths in cancer drug trialsAn increased risk of deaths for patients in clinical trials receiving this cancer drug and two other drugs led FDA to stop the clinical trials.
FDA Warning on KeytrudaAfter trials halted, FDA issues warning on off-label use of the drug.
A First: Cancer Drug Is Approved on Genetic Basis, Not Tumor Location
A First: Cancer Drug Is Approved on Genetic Basis, Not Tumor LocationPembrolizumab gets FDA approval for cancers with a certain biomarker.
Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Uro Pipeline: FDA accepts two supplemental applications for mUC agentOther pipeline developments include efficacy results for a bladder and prostate cancer drug, an infertility tool to predict sperm quality, the initiation of an immunotherapy combination for mUC, and more.
New Parkinson's drug, 2 others approvedFDA approved safinamide (Xadago, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease. FDA also approved new treatments for classical Hodgkin lymphoma and pemphigus vulgaris, a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.
Uro Pipeline: FDA committee votes in favor of nocturia treatment approvalOther pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
Merck value rises after new Keytruda approvalMerck’s Wall Street value is climbing after its cancer drug pembrolizumab (Keytruda) received yet another approval from FDA.
Huge coalition to advance cancer treatments